ClinicalTrials.gg

Program

givastomig

Also written as “Givastomig”, “TJ033721 (givastomig)” and “TJ033721 (givastomig) , nivolumab, chemotherapy”.

Its studies are mostly in Neoplasm Metastasis, led by I-Mab Biopharma US.

Furthest: phase 2, since Feb 11, 20262 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
I-Mab Biopharma US22 open or runningphase 2since Feb 11, 2026May 20, 2021Dec 2026phase 1 · NCT04900818

Also a collaborator on its studies: Bristol-Myers Squibb.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 20, 2021First study: phase 1 study in Neoplasm MetastasisFirst studyNCT04900818 · 330 planned · United States, China
  2. Feb 11, 2026Phase 2 study in Neoplasm MetastasisPhase 2 reachedNCT07432295 · 180 planned · United States, China, Japan

Ahead

  1. Dec 2026Primary completion: phase 1 study in Neoplasm MetastasisNCT04900818
  2. Mar 2030Primary completion: phase 2 study in Neoplasm MetastasisNCT07432295

TargetBeta

CLDN18 →read by rule
“A bispecific antibody composed of a human, Fc-silenced immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18) ”NCIt, by rule

Other programs on CLDN18

ProgramCompanyFurthest phaseStudies
zolbetuximabruleAstellas Pharmaphase 412
sonesitatug vedotinAstraZenecaphase 37
garetatug rezetecanJiangsu HengRui Medicinephase 37
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905ruleQilu Pharmaceuticalphase 36
tecotabart vedotinSino Biopharmaceuticalphase 36
arcotatug tavatecanruleInnovent Biologicsphase 35
terallethrinruleFutureGen Biopharmaceutical (Beijing)phase 33
Anti-Claudin 18.2 Antibody-drug Conjugate BL-M05D1biokin-shanghai-biopharmaceutical-co-ltdphase 33
emaretamigruleAstellas Pharmaphase 33
Anti-Claudin 18.2 Antibody-drug Conjugate MK-1200ruleSichuan Kelun Pharmaceuticalphase 23
Anti-Claudin 18.2 Antibody-drug Conjugate ASP546CruleAstellas Pharmaphase 22
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863AstraZenecaphase 21

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07432295Neoplasm Metastasis · United States, China, Japan2RecruitingMar 2030180
NCT04900818Neoplasm Metastasis · United States, China1RecruitingDec 2026330

How it is read

Names in the registry

  • “Givastomig”, 1 entry
  • “TJ033721 (givastomig)”, 1 entry
  • “TJ033721 (givastomig) , nivolumab, chemotherapy”, 1 entry
  • “TJ033721 (givastomig), chemotherapy”, 1 entry
  • “TJ033721 (givastomig), durvalumab, chemotherapy”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.